Invention Grant
US08409573B2 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
失效
抗CD71单克隆抗体及其用于治疗恶性肿瘤细胞的用途
- Patent Title: Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
- Patent Title (中): 抗CD71单克隆抗体及其用于治疗恶性肿瘤细胞的用途
-
Application No.: US11922025Application Date: 2006-06-14
-
Publication No.: US08409573B2Publication Date: 2013-04-02
- Inventor: Laurence Boumsell , Jean Kadouche , Armand Bensussan
- Applicant: Laurence Boumsell , Jean Kadouche , Armand Bensussan
- Applicant Address: FR Evry FR Paris
- Assignee: Mablife,Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee: Mablife,Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee Address: FR Evry FR Paris
- Agency: Foley & Lardner LLP
- International Application: PCT/IB2006/002331 WO 20060614
- International Announcement: WO2007/000671 WO 20070104
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
Public/Granted literature
- US20110311544A1 Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells Public/Granted day:2011-12-22
Information query
